NCT03288584 is a clinical trial of Tocilizumab (Actemra®) in Rheumatoid Arthritis, sponsored by University of Athens.

Who is sponsoring NCT03288584?

NCT03288584 is sponsored by University of Athens.

What drugs are being tested in NCT03288584?

Interventions in NCT03288584: Tocilizumab (Actemra®), Other biological agent, Corticosteroid and non-biological agents..

What condition does NCT03288584 study?

NCT03288584 studies Rheumatoid Arthritis, Inflammation.

Is NCT03288584 still recruiting?

NCT03288584 is currently status unknown. Last updated 3 April 2020.

Last reviewed 2020-04-03 · How we verify

NCT03288584

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effects of Interleukin-6 Inhibition on Vascular, Endothelial and Left Ventricular Function in Rheumatoid Arthritis

Status unknown Last updated 3 April 2020

What this trial tests

trial testing Tocilizumab (Actemra®) in Rheumatoid Arthritis in 60 participants. Status unknown.

Timeline

27 October 2017

Primary endpoint
31 December 2020

31 December 2020

Quick facts

Lead sponsor	University of Athens
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	60
Start date	27 October 2017
Primary completion	31 December 2020
Estimated completion	31 December 2020
Sites	1 location across Greece

Drugs / interventions tested

Tocilizumab (Actemra®) — full drug profile →
Other biological agent — full drug profile →
Corticosteroid and non-biological agents. — full drug profile →

Conditions studied

Rheumatoid Arthritis — all drugs for Rheumatoid Arthritis →
Inflammation — all drugs for Inflammation →

Sponsor

University of Athens

Who can join

Adults 18 to 80, any sex, with Rheumatoid Arthritis or Inflammation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Recent studies show beneficial effect of the inhibition of interleukin-6 (IL-6) activity on vascular and left ventricular (LV) function. The purpose of this study is to investigate whether anakinra, an IL-6 receptor antagonist, improves vascular, endothelial and LV function in patients with rheumatoid arthritis (RA).

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Tocilizumab improves oxidative stress and endothelial glycocalyx: A mechanism that may explain the effects of biological treatment on COVID-19.
Ikonomidis I, Pavlidis G, Katsimbri P, Lambadiari V, et al · · 2020 · cited 50× · PMID 32822775 · DOI 10.1016/j.fct.2020.111694
Differential effects of inhibition of interleukin 1 and 6 on myocardial, coronary and vascular function.
Ikonomidis I, Pavlidis G, Katsimbri P, Andreadou I, et al · · 2019 · cited 43× · PMID 30859382 · DOI 10.1007/s00392-019-01443-9
Inhaled RNA Therapeutics for Obstructive Airway Diseases: Recent Advances and Future Prospects.
Xu Y, Thakur A, Zhang Y, Foged C. · · 2021 · cited 24× · PMID 33525500 · DOI 10.3390/pharmaceutics13020177
Immunotherapy for the rheumatoid arthritis-associated coronary artery disease: promise and future.
Wang L, Zhang Y, Zhang SY. · · 2019 · cited 11× · PMID 31855971 · DOI 10.1097/cm9.0000000000000530
Sympathetic nerve-adipocyte interactions in response to acute stress.
Santos GSP, Costa AC, Picoli CC, Rocha BGS, et al · · 2022 · cited 8× · PMID 34735579 · DOI 10.1007/s00109-021-02157-0

Verify or expand the search:

Other trials of Tocilizumab (Actemra®)

Trials testing the same drug.

NCT07334379 — Interleukin-6 Guided Treatment With Dexamethasone or Tocilizumab in Patients Hospitalized With Acute Respiratory Symptom · Phase 2 · recruiting

Other recruiting trials for Rheumatoid Arthritis

Currently open trials in the same condition.

NCT07433335 — A Study to Assess the Safety and Tolerability of SR-878 in Patients With Rheumatoid Arthritis · Phase 1 · recruiting
NCT07491016 — Efficacy and Safety of Telitacicept Combined With Baricitinib for Refractory Rheumatoid Arthritis · recruiting
NCT07171983 — A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986454 in Participants With Rheumatoid Arthritis · Phase 1 · recruiting
NCT07246096 — Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Rel · EARLY_PHASE1 · recruiting
NCT07363590 — A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004) · Phase 1 · recruiting

Other University of Athens trials

Trials by the same sponsor.

NCT07469943 — The Effect of Sodium Glucose Co-trnasportert Type 2 Inhibitors on Arterial Stiffness, Endothelial Glycocalyx Thickness a · recruiting
NCT07254819 — Cotinus Coggygria Mouthwash and Halitosis and Oral Hygiene in Orthodontic Patients · NA · completed
NCT07069010 — Burnout Syndrome in the Intensive Care Unit Before and During a Palliative Care Trial · recruiting
NCT06766097 — Chios Mastic Toothpaste and Halitosis and Oral Hygiene in Orthodontic Patients · NA · not yet recruiting
NCT06885970 — The Effect of Cytisine Treatment for Smoking Cessation on Cardiovascular Function in Adult Smokers · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03288584 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Athens
Last refreshed: 3 April 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03288584.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing